Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 20/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16712586 | 0.92 | CHEK1 (0.47) | CHEK1 | |
| SCHEMBL16712616 | 0.91 | CHEK1 (0.61) | CHEK1 | |
| SCHEMBL6828183 | 0.90 | CHEK1 (0.50) | CHEK1 | |
| SCHEMBL4847638 | 0.85 | ALDH1A1 (0.53) | CHEK1 | |
| SCHEMBL6827521 | 0.84 | CHEK1 (0.55) | CHEK1 | |
| SCHEMBL6210050 | 0.84 | CHEK1 (0.56) | CHEK1 | |
| SCHEMBL6210173 | 0.84 | CHEK1 (0.65) | CHEK1 | |
| SCHEMBL16712563 | 0.83 | CHEK1 (0.54) | CHEK1 | |
| SCHEMBL6209683 | 0.83 | CHEK1 (0.54) | CHEK1 | |
| SCHEMBL6209469 | 0.81 | CHEK1 (0.52) | CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1606268-B1 | 5,10-DIHYDRO-11H-DIBENZO[B,E][1,4]DIAZEPIN-11-ONE AS KINASE INHIBITORS | ABBVIE INC (US) | 2015-05-20 | — | — | EP | claimed |
| US-20040254159-A1 | Heterocyclic kinase inhibitors | ABBOTT LABORATORIES | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254159-A1 | Heterocyclic kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | CHEK1 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.